Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain

F. Blandini, R. Fancellu, F. Orzi, G. Conti, R. Greco, C. Tassorelli, G. Nappi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this study, we mapped the cerebral expression of Fos protein following intrastriatal stimulation of D1 or D2 receptors, in freely moving animals. Animals treated with the D1 agonist SKF 38393 showed massive Fos increases in the cerebral cortex, ipsilaterally to the injected striatum, which were counteracted by systemic administration of D1 antagonist SCH 23390. Conversely, D2 agonist quinpirole suppressed cortical expression of Fos, while systemic administration of D2 antagonist eticlopride relieved this blockade. As for the basal ganglia, Fos was consistently expressed only in the injected striatum of rats receiving SKF 38393. These results show that striatal dopamine receptors may play a role in the modulation of cortical activity. They also provide new information on a class of drugs - the dopamine agonists - whose role in the therapeutic strategy of Parkinson's disease is continuously evolving.

Original languageEnglish
JournalNeurological Sciences
Volume23
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2002

Fingerprint

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
eticlopride
Dopamine Agonists
Quinpirole
Corpus Striatum
Dopamine Receptors
Brain
Basal Ganglia
Cerebral Cortex
Parkinson Disease
Pharmaceutical Preparations
Proteins
Therapeutics
SCH 23390

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. / Blandini, F.; Fancellu, R.; Orzi, F.; Conti, G.; Greco, R.; Tassorelli, C.; Nappi, G.

In: Neurological Sciences, Vol. 23, No. SUPPL. 2, 09.2002.

Research output: Contribution to journalArticle

@article{d8d55d967d5543ec9a534842a9989ace,
title = "Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain",
abstract = "In this study, we mapped the cerebral expression of Fos protein following intrastriatal stimulation of D1 or D2 receptors, in freely moving animals. Animals treated with the D1 agonist SKF 38393 showed massive Fos increases in the cerebral cortex, ipsilaterally to the injected striatum, which were counteracted by systemic administration of D1 antagonist SCH 23390. Conversely, D2 agonist quinpirole suppressed cortical expression of Fos, while systemic administration of D2 antagonist eticlopride relieved this blockade. As for the basal ganglia, Fos was consistently expressed only in the injected striatum of rats receiving SKF 38393. These results show that striatal dopamine receptors may play a role in the modulation of cortical activity. They also provide new information on a class of drugs - the dopamine agonists - whose role in the therapeutic strategy of Parkinson's disease is continuously evolving.",
author = "F. Blandini and R. Fancellu and F. Orzi and G. Conti and R. Greco and C. Tassorelli and G. Nappi",
year = "2002",
month = "9",
doi = "10.1007/s100720200068",
language = "English",
volume = "23",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain

AU - Blandini, F.

AU - Fancellu, R.

AU - Orzi, F.

AU - Conti, G.

AU - Greco, R.

AU - Tassorelli, C.

AU - Nappi, G.

PY - 2002/9

Y1 - 2002/9

N2 - In this study, we mapped the cerebral expression of Fos protein following intrastriatal stimulation of D1 or D2 receptors, in freely moving animals. Animals treated with the D1 agonist SKF 38393 showed massive Fos increases in the cerebral cortex, ipsilaterally to the injected striatum, which were counteracted by systemic administration of D1 antagonist SCH 23390. Conversely, D2 agonist quinpirole suppressed cortical expression of Fos, while systemic administration of D2 antagonist eticlopride relieved this blockade. As for the basal ganglia, Fos was consistently expressed only in the injected striatum of rats receiving SKF 38393. These results show that striatal dopamine receptors may play a role in the modulation of cortical activity. They also provide new information on a class of drugs - the dopamine agonists - whose role in the therapeutic strategy of Parkinson's disease is continuously evolving.

AB - In this study, we mapped the cerebral expression of Fos protein following intrastriatal stimulation of D1 or D2 receptors, in freely moving animals. Animals treated with the D1 agonist SKF 38393 showed massive Fos increases in the cerebral cortex, ipsilaterally to the injected striatum, which were counteracted by systemic administration of D1 antagonist SCH 23390. Conversely, D2 agonist quinpirole suppressed cortical expression of Fos, while systemic administration of D2 antagonist eticlopride relieved this blockade. As for the basal ganglia, Fos was consistently expressed only in the injected striatum of rats receiving SKF 38393. These results show that striatal dopamine receptors may play a role in the modulation of cortical activity. They also provide new information on a class of drugs - the dopamine agonists - whose role in the therapeutic strategy of Parkinson's disease is continuously evolving.

UR - http://www.scopus.com/inward/record.url?scp=0036756966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036756966&partnerID=8YFLogxK

U2 - 10.1007/s100720200068

DO - 10.1007/s100720200068

M3 - Article

VL - 23

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -